Article

Upgrade for aberrometer

WaveTec Vision has introduced an upgrade and an unlimited-use pricing model for its intraoperative wavefront aberrometer (ORange).

Aliso Viejo, CA-WaveTec Vision has introduced an upgrade and an unlimited-use pricing model for its intraoperative wavefront aberrometer (ORange).

Software version 2.6 includes more than 20 new functions, with a special focus on accuracy updates and data sharing. New features include improvements to the post-refractive IOL power calculation algorithm and a warning to the user when a measurement is not consistent with the preoperative biometry of the patient.

“With [the aberrometer], cataract surgeons can now validate their lens power calculations and manage astigmatism during surgery so they can precisely predict and customize how their patients will see following the procedure,” said Tom Frinzi, WaveTec chief executive officer.

The new pricing model is designed to make custom cataract surgery more affordable and accessible to surgeons and their patients. Moving away from a per-use cost basis, practices will now be charged a flat rate of $3,000 per month for unlimited use of the technology.  Cost of the equipment is about $30,000, including the first year’s service contract; subsequent annual service contracts are priced at $3,000.

“By making it easier for surgeons both to purchase and perform . . . custom cataract surgery, we are able to assist in delivering optimal refractive outcomes to patients,” Frinzi said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.